News of Note—Vaccine exemption 'hot spots,' NIAID’s RSV vaccine study and more


Here is some other vaccine news of note for the week.

> Some regions in the 18 states that allow parents to opt their children out of school immunization requirements for nonmedical reasons could be vulnerable to vaccine-preventable diseases, a new study shows. The Washington Post article

> The National Institute of Allergy and Infectious Diseases (NIAID) has started a human study of an intranasal vaccine against respiratory syncytial virus (RSV). Release

> Combining a pre-erythrocytic malaria vaccine like GlaxoSmithKline’s Mosquirix with a transmission-blocking vaccine, which prevents mosquitoes from transferring the parasites, could boost protection to around 91%, a study in mice shows. Release

> Adel Mahmoud, M.D., Ph.D., who was president of Merck Vaccines from 1998 to 2006, died on June 11. He oversaw the creation of HPV vaccine Gardasil, rotavirus vaccine RotaTeq, shingles vaccine Zostavax, and measles, mumps, rubella and chicken pox combo shot ProQuad. The New York Times article

Suggested Articles

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.